Oxybutynin Hydrochloride

Phase 3Small molecule

Astellas

Oxybutynin Hydrochloride is one of 6 small molecule programs targeting Neurogenic bladder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurogenic BladderNot yet recruiting

Neurogenic BladderPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Neurogenic Bladder

#DrugCompanyPhaseTrials

Rapaflo

AbbVie

Approved

1 2

Minipress

Oxytrol

2 4

Toviaz

Uroxatral

Oxybutynin Hydrochloride

Astellas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Neurogenic Bladder

NCT07027020

Clinical

Trials by Indication[1]

Neurogenic bladder1 trial

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Not yet recruiting·—·Phase 3·NCT07027020·60 enrolled

Multiple Sclerosis1 trial

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

Completed· Astellas logo

Astellas·Phase 4·NCT00629642·249 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oxybutynin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxybutynin Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxybutynin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Astellas

Oxybutynin Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neurogenic bladder1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News